Another possible reason for the insensitivity of cancer cells to sorafenib-induced ferroptosis is that LIFR expression is downregulated in a wide range of tumor types, including liver, bladder, breast, colon, kidney, lung, rectum, and thyroid cancers (TCGA data analysis, Supplementary Fig. 10). This evidence concerns the gene LIFR and thyroid cancer.